Eight Year Results in the Treatment of Keloids by HDR Brachytherapy

Heather Jones, MD
University of Pennsylvania Cancer Center
Ultima Vez Modificado: 5 de noviembre del 2001

Share article


English

Presenter: B. Guix
Presenter's Affiliation: Radiation Oncology, Fundacio IMOR, Barcelona, Spain
Type of Session: Scientific

Background
Keloids form as a result of abnormal growth of scar tissue usually after injury to the skin. The incidence ranges form 3 to 15%. The formation of keloids can result in itching, burning and bleeding. This prospective study analyzes the treatment of keloids by HDR brachytherapy with or without previous surgery.

Materials and Methods

  • One hundred and sixty nine patients with keloid scar were treated with HDR brachytherapy
  • One hundred and thirty four patients were females and 35 males.
  • Seventy-seven keloids were on the face, 73 on the trunk and 19 on the extremities. The average length of the keloid was 4.2 cm and the average width was 1.8 cm.
  • One hundred and forty seven patients had surgical excision of the keloid tissue prior to brachytherapy and 22 were treated exclusively by HDR brachytherapy.
  • Brachytherapy was initiated in the first 24 hours after surgery.
  • 4 fractions of 500 cGy at 1 cm from the center of the catheter with geometrical dose distribution optimization were given, in 24 hour (at 09.00, 15.00, 21.00 and 09.00).
  • In those patients not treated by surgery, the plastic tube was placed under the skin with local anesthesia and 6 fractions of 300 cGy in 2 two days were given.

    Results

  • 8 patients (4.7 %) experienced a recurrence of their keloid
  • 5/147 (3.4%) patients treated with surgery and HDR had a recurrence
  • 3/22 (13.6 %) treated exclusively by HDR brachytherapy experienced a recurrence.
  • Cosmetic results were considered to be good or excellent in 130/147 patients treated with prior excision and in 17/22 patients without surgery. Ten patients developed skin pigmentation changes and 12 patients telangiectasias.

    Author's Conclusions
    HDR brachytherapy was a highly effective treatment of keloids. It was well tolerated and no significant side effects were noted. It was preferably to have the keloid completely excised prior to HDR brachytherapy. Brachytherapy was preferable to superficial x-rays or low energy electrons because the more selective deposition of radiation in the tissue, and the less amount of normal tissue irradiated. HDR was preferable to LDR brachytherapy because it can be done in an out-patient basis, its relatively low cost, excellent radiation protection and better dose distribution obtained. This allowed a high local control with no significant HDR brachytherapy related sequelae or complication.

    Clinical/Scientific Implications
    This study indicates that treatment of keloids with HDR results gives good cosmesis and reduces dose to normal tissue, which is paramount in the treatment of non-malignant disease with radiation. The long-term data would also seem to indicate no excessive late effects with the increase in dose.

    English
    News
    ASTRO: Combination Therapy Beneficial in Prostate Cancer

    Nov 24, 2014 - Long-term survival may be increased in medium-risk prostate cancer patients who receive short-term androgen deprivation therapy before and during radiation treatment compared with men who receive radiation alone. In addition, proton beam therapy may be associated with a decreased risk of disease recurrence after 10 years and has minimal side effects after one year, according to research presented at the 51st Annual Meeting of the American Society for Radiation Oncology, held from Nov. 1 to 5 in Chicago.



  • I Wish You Knew

    How cancer patients have changed my life

    View More



    Blogs and Web Chats

    OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




    OncoLink OncoPilot

    Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

    Más información